These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32297783)

  • 1. Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.
    Gordon CT; Fabiano GA; Hulme KF; Sodano SM; Adragna M; Lim R; Stanford S; Janikowski L; Bufalo B; Rodriguez Z; Swiatek D
    Exp Clin Psychopharmacol; 2021 Aug; 29(4):308-318. PubMed ID: 32297783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
    Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
    BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
    J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
    Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
    Castells X; Blanco-Silvente L; Cunill R
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Goodman DW; Kollins SH; Weisler RH; Krishnan S; Zhang Y; Biederman J;
    J Clin Psychiatry; 2008 Sep; 69(9):1364-73. PubMed ID: 19012818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
    Martin PT; Corcoran M; Zhang P; Katic A
    Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
    Coghill DR; Banaschewski T; Lecendreux M; Zuddas A; Dittmann RW; Otero IH; Civil R; Bloomfield R; Squires LA
    Eur Child Adolesc Psychiatry; 2014 Feb; 23(2):61-8. PubMed ID: 23708466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
    Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.